Two is better than one. Combining anti-spastic drugs

Stroet et al. Treatment failure of intrathecal baclofen and supra-additive effect of nabiximols in multiple sclerosis-related spasticity: a case report. Ther Adv Neurol Disord. 2013 May;6(3):199-203.

Multiple sclerosis (MS)-related spasticity is associated with disability and impairment in quality of life. We report on a patient with secondary progressive MS and spastic tetraparesis (Expanded Disability Status Scale score 8.5). The right arm exhibited flexor spasticity resulting in functional disability despite multimodal symptomatic treatment. Intrathecal baclofen led to side effects despite decreasing efficacy. Low-dose nabiximols improved spasticity and function with recovery of daily-life activities and spasticity-related symptoms. Reduction of intrathecal baclofen ameliorated adverse drug reactions. Add-on cannabinoid therapy was effective in therapy-refractory spasticity with supra-additive effect in combining intrathecal baclofen and nabiximols, hypothetically explained by mutually complementing mechanisms of action.


Nabiximols is another name for sativex so this study says that balcofen causes side effects but if cannabis was added to the treatment then there  was increased efficacy and this may allow you to reduce doses of drugs that cause the side effect, Good management of drug mixtures can work wonders. 

CoI: MD is developing competing agents to treat spasticity.

Labels: ,